Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Assets Average (2021 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Assets Average for 5 consecutive years, with $135.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Assets Average fell 29.69% year-over-year to $135.8 million, compared with a TTM value of $135.8 million through Jun 2025, down 29.69%, and an annual FY2023 reading of $242.4 million, down 12.02% over the prior year.
  • Assets Average was $135.8 million for Q2 2025 at Barinthus Biotherapeutics, down from $187.7 million in the prior quarter.
  • Across five years, Assets Average topped out at $285.6 million in Q2 2022 and bottomed at $108.6 million in Q1 2021.
  • Average Assets Average over 5 years is $229.7 million, with a median of $246.0 million recorded in 2023.
  • The sharpest move saw Assets Average skyrocketed 161.03% in 2022, then decreased 29.69% in 2025.
  • Year by year, Assets Average stood at $268.6 million in 2021, then rose by 1.56% to $272.8 million in 2022, then dropped by 18.55% to $222.2 million in 2023, then fell by 15.53% to $187.7 million in 2024, then fell by 27.67% to $135.8 million in 2025.
  • Business Quant data shows Assets Average for BRNS at $135.8 million in Q2 2025, $187.7 million in Q3 2024, and $193.1 million in Q2 2024.